The adjuvanted recombinant nanoparticle-based vaccine GBP510/AS03 shows a clinically acceptable safety profile and immunogenicity results comparable to that of the currently available ChAdOx1-S ...
(RTTNews) - AstraZeneca's (AZN.L, AZN) COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant], formerly AZD1222), has been granted full marketing authorization in the European Union, the British drug ...
A recent eClinicalMedicine study evaluated the safety and efficacy of the GBP510 vaccine, which contains self-assembling nanoparticles, against severe acute respiratory syndrome coronavirus-2 ...
In a recent study posted to the medRxiv* pre-print server, researchers evaluated the immunogenicity of booster doses of alum-adjuvanted SCB-2019 vaccine candidate's three formulations. They tested ...
During the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, several new viral variants have emerged, leading to the virus becoming more contagious. However, efficient immune ...
Assessment of the safety and efficacy of vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in different populations is essential, as is investigation of the efficacy of ...
The video begins with a man sitting at a counter describing his COVID-19 vaccine side effects. “The only problem is that everywhere I go -- everywhere I go everything is starting to connect to my, man ...
The University of Oxford partnered with the British-Swedish company AstraZeneca to develop and test a coronavirus vaccine known as ChAdOx1 nCoV-19 or AZD1222. A large clinical trial showed the vaccine ...
Clinical Research Fellow at the Centre for Clinical Vaccinology and Tropical Medicine, Jenner Institute, and PhD Candidate in Clinical Medicine, University of Oxford Rebecca Ashfield consults for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback